ELI LILLY & Co (LLY) vs Merck & Co., Inc. (MRK)
Side-by-side comparison from SEC filings: latest annual financials, insider activity and institutional ownership.
| Metric | LLY | MRK |
|---|---|---|
| Sector | Health Care | Health Care |
| Latest fiscal year | FY2025 | FY2025 |
| Revenue | $65.18B | $65.01B |
| Revenue growth (YoY) | ▲ 44.7% | ▲ 1.3% |
| Net income | $20.64B | $18.25B |
| Gross margin | 83.0% | 74.8% |
| Diluted EPS | $22.95 | $7.28 |
| Insider net (6 mo) | −37.3K sh • 5 sells • 0 buys | −101.8K sh • 9 sells • 0 buys |
| Institutional owners | 72 | 67 |
| Institutional value held | $563.64B | $177.99B |
| Next earnings (est.) | Around Feb 3, 2027 | Feb 2, 2027 |
Figures from each company's SEC filings (latest reported fiscal year; fiscal calendars may differ). Next-earnings dates are estimates from historical filing patterns.
About ELI LILLY & Co (LLY)
Eli Lilly and Company, incorporated in Indiana in 1901 to succeed a drug manufacturing business founded in Indianapolis in 1876, discovers, develops, manufactures, and markets human pharmaceutical products. It operates in a single business segment. Read more →
About Merck & Co., Inc. (MRK)
Merck & Co., Inc. is a global health care company that delivers innovative health solutions through prescription medicines, including biologic therapies, vaccines and animal health products. Its operations are managed principally on a product basis. Read more →
Source: SEC EDGAR.